{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:12:40Z","timestamp":1790179960987,"version":"4.1.0"},"reference-count":140,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cannabidiol (CBD), the major nonpsychoactive Cannabis constituent, has been proposed for the treatment of a wide panel of neurological and neuropsychiatric disorders, including anxiety, schizophrenia, epilepsy and drug addiction due to the ability of its versatile scaffold to interact with diverse molecular targets that are not restricted to the endocannabinoid system. Albeit the molecular mechanisms responsible for the therapeutic effects of CBD have yet to be fully elucidated, many efforts have been devoted in the last decades to shed light on its complex pharmacological profile. In particular, an ever-increasing number of molecular targets linked to those disorders have been identified for this phytocannabinoid, along with the modulatory effects of CBD on their cascade signaling. In this view, here we will try to provide a comprehensive and up-to-date overview of the molecular basis underlying the therapeutic effects of CBD involved in the treatment of neurological and neuropsychiatric disorders.<\/jats:p>","DOI":"10.3390\/ijms22094876","type":"journal-article","created":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T11:06:01Z","timestamp":1620212761000},"page":"4876","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["The (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric Disorders: Molecular Mechanisms and Targets"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9243-1307","authenticated-orcid":false,"given":"Rosa Maria","family":"Vitale","sequence":"first","affiliation":[{"name":"Institute of Biomolecular Chemistry, National Research Council (ICB-CNR), Via Campi Flegrei 34, 80078 Pozzuoli, NA, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4480-8370","authenticated-orcid":false,"given":"Fabio Arturo","family":"Iannotti","sequence":"additional","affiliation":[{"name":"Institute of Biomolecular Chemistry, National Research Council (ICB-CNR), Via Campi Flegrei 34, 80078 Pozzuoli, NA, Italy"},{"name":"Endocannabinoid Research Group (ERG), Institute of Biomolecular Chemistry, National Research Council (ICB-CNR), Via Campi Flegrei 34, 80078 Pozzuoli, NA, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6439-7575","authenticated-orcid":false,"given":"Pietro","family":"Amodeo","sequence":"additional","affiliation":[{"name":"Institute of Biomolecular Chemistry, National Research Council (ICB-CNR), Via Campi Flegrei 34, 80078 Pozzuoli, NA, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/epi.12631","article-title":"Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders","volume":"55","author":"Devinsky","year":"2014","journal-title":"Epilepsia"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/bph.14440","article-title":"Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors","volume":"176","author":"Tham","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s13311-015-0373-7","article-title":"Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage","volume":"12","author":"Hurd","year":"2015","journal-title":"Neurotherapeutics"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/0040-4020(63)85022-X","article-title":"Hashish\u2014I","volume":"19","author":"Mechoulam","year":"1963","journal-title":"Tetrahedron"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMra1004418","article-title":"Drug-Resistant Epilepsy","volume":"365","author":"Kwan","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/epi.12635","article-title":"The case for assessing cannabidiol in epilepsy","volume":"55","author":"Cilio","year":"2014","journal-title":"Epilepsia"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Silvestro, S., Mammana, S., Cavalli, E., Bramanti, P., and Mazzon, E. (2019). Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials. Molecules, 24.","DOI":"10.3390\/molecules24081459"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.neubiorev.2020.01.014","article-title":"The anticonvulsant effects of cannabidiol in experimental models of epileptic seizures: From behavior and mechanisms to clinical insights","volume":"111","author":"Leite","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_12","first-page":"485","article-title":"Emerging Use of Epidiolex (Cannabidiol) in Epilepsy","volume":"25","author":"Scutt","year":"2020","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Watt, G., and Karl, T. (2017). In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer\u2019s Disease. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00020"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/FBP.0000000000000247","article-title":"The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer\u2019s disease","volume":"28","author":"Karl","year":"2017","journal-title":"Behav. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.neulet.2006.01.047","article-title":"Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in \u03b2-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-\u03baB involvement","volume":"399","author":"Esposito","year":"2006","journal-title":"Neurosci. Lett."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.freeradbiomed.2011.02.021","article-title":"Cannabidiol protects against hepatic ischemia\/reperfusion injury by attenuating inflammatory signaling and response, oxidative\/nitrative stress, and cell death","volume":"50","author":"Mukhopadhyay","year":"2011","journal-title":"Free Radic. Biol. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00109-005-0025-1","article-title":"The marijuana component cannabidiol inhibits \u03b2-amyloid-induced tau protein hyperphosphorylation through Wnt\/\u03b2-catenin pathway rescue in PC12 cells","volume":"84","author":"Esposito","year":"2006","journal-title":"J. Mol. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10571-013-9984-x","article-title":"Cannabinoid Effects on \u03b2 Amyloid Fibril and Aggregate Formation, Neuronal and Microglial-Activated Neurotoxicity In Vitro","volume":"34","author":"Janefjord","year":"2014","journal-title":"Cell. Mol. Neurobiol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Esposito, G., Scuderi, C., Valenza, M., Togna, G.I., Latina, V., De Filippis, D., Cipriano, M., Carrat\u00f9, M.R., Iuvone, T., and Steardo, L. (2011). Cannabidiol Reduces A\u03b2-Induced Neuroinflammation and Promotes Hippocampal Neurogenesis through PPAR\u03b3 Involvement. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0028668"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Scuderi, C., Steardo, L., and Esposito, G. (2013). Cannabidiol Promotes Amyloid Precursor Protein Ubiquitination and Reduction of Beta Amyloid Expression in SHSY5Y(APP+) Cells Through PPAR\u03b3 Involvement. Phytother. Res.","DOI":"10.1002\/ptr.5095"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1111\/febs.12335","article-title":"The hallmarks of Parkinson\u2019s disease","volume":"280","author":"Antony","year":"2013","journal-title":"FEBS J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S415","DOI":"10.2741\/S415","article-title":"Parkinson\u2019s disease a review","volume":"S6","author":"Beitz","year":"2014","journal-title":"Front. Biosci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.brainres.2006.11.063","article-title":"Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson\u2019s disease: Importance of antioxidant and cannabinoid receptor-independent properties","volume":"1134","author":"Ramos","year":"2007","journal-title":"Brain Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00406-019-00982-6","article-title":"Is cannabidiol the ideal drug to treat non-motor Parkinson\u2019s disease symptoms?","volume":"269","author":"Crippa","year":"2019","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2174\/1871527313666140612114838","article-title":"Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis sativa","volume":"13","author":"Schier","year":"2014","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1601-5215.2011.00579.x","article-title":"Administration of cannabidiol and imipramine induces antidepressant-like effects in the forced swimming test and increases brain-derived neurotrophic factor levels in the rat amygdala","volume":"23","author":"Stringari","year":"2011","journal-title":"Acta Neuropsychiatr."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0091-3057(96)00169-4","article-title":"Antidepressant-Like Effect of Brain-derived Neurotrophic Factor (BDNF)","volume":"56","author":"Siuciak","year":"1997","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/(SICI)1097-4547(19980415)52:2<149::AID-JNR3>3.0.CO;2-A","article-title":"BDNF induction of tryptophan hydroxylase mRNA levels in the rat brain","volume":"52","author":"Siuciak","year":"1998","journal-title":"J. Neurosci. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0006-8993(02)02505-2","article-title":"Modulation of neurotransmitter release induced by brain-derived neurotrophic factor in rat brain striatal slices in vitro","volume":"941","author":"Goggi","year":"2002","journal-title":"Brain Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/sj.npp.1301571","article-title":"Interaction between BDNF and Serotonin: Role in Mood Disorders","volume":"33","author":"Martinowich","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"di Giacomo, V., Chiavaroli, A., Recinella, L., Orlando, G., Cataldi, A., Rapino, M., Di Valerio, V., Ronci, M., Leone, S., and Brunetti, L. (2020). Antioxidant and Neuroprotective Effects Induced by Cannabidiol and Cannabigerol in Rat CTX-TNA2 Astrocytes and Isolated Cortexes. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21103575"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1055\/s-0042-106764","article-title":"Pharmakotherapie bei Angsterkrankungen","volume":"84","author":"Zwanzger","year":"2016","journal-title":"Fortschritte der Neurol. \u00b7 Psychiatr."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","article-title":"Cannabidiol as a Potential Treatment for Anxiety Disorders","volume":"12","author":"Blessing","year":"2015","journal-title":"Neurotherapeutics"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Shannon, S. (2019). Cannabidiol in Anxiety and Sleep: A Large Case Series. Perm. J., 23.","DOI":"10.7812\/TPP\/18-041"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1111\/bph.14226","article-title":"Cannabidiol regulates behavioural alterations and gene expression changes induced by spontaneous cannabinoid withdrawal","volume":"175","author":"Navarrete","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.tins.2016.12.006","article-title":"Cannabidiol: Swinging the Marijuana Pendulum From \u2018Weed\u2019 to Medication to Treat the Opioid Epidemic","volume":"40","author":"Hurd","year":"2017","journal-title":"Trends Neurosci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"SART.S25081","DOI":"10.4137\/SART.S25081","article-title":"Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the Evidence","volume":"9","author":"Cata","year":"2015","journal-title":"Subst. Abus. Res. Treat."},{"key":"ref_38","first-page":"972","article-title":"Autism Spectrum Disorder: Primary Care Principles","volume":"94","author":"Sanchack","year":"2016","journal-title":"Am. Fam. Physician"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/HRP.0000000000000002","article-title":"Autism Spectrum Disorder Genetics","volume":"22","author":"Talkowski","year":"2014","journal-title":"Harv. Rev. Psychiatry"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/jcpp.12501","article-title":"Annual Research Review: The role of the environment in the developmental psychopathology of autism spectrum condition","volume":"57","author":"Mandy","year":"2016","journal-title":"J. Child Psychol. Psychiatry"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Zamberletti, E., Gabaglio, M., and Parolaro, D. (2017). The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18091916"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13229-018-0203-y","article-title":"Plasma anandamide concentrations are lower in children with autism spectrum disorder","volume":"9","author":"Karhson","year":"2018","journal-title":"Mol. Autism"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/1098-2779(2000)6:4<300::AID-MRDD9>3.0.CO;2-R","article-title":"Epilepsy and epileptiform EEG: Association with autism and language disorders","volume":"6","author":"Tuchman","year":"2000","journal-title":"Ment. Retard. Dev. Disabil. Res. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.yebeh.2015.03.017","article-title":"Autism spectrum disorder and epilepsy: Disorders with a shared biology","volume":"47","author":"Lee","year":"2015","journal-title":"Epilepsy Behav."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1007\/s10803-018-3808-2","article-title":"Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems\u2014A Retrospective Feasibility Study","volume":"49","author":"Aran","year":"2019","journal-title":"J. Autism Dev. Disord."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Fleury-Teixeira, P., Caixeta, F.V., Ramires da Silva, L.C., Brasil-Neto, J.P., and Malcher-Lopes, R. (2019). Effects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder Symptoms: An Observational Study of 18 Participants Undergoing Compassionate Use. Front. Neurol., 10.","DOI":"10.3389\/fneur.2019.01145"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","article-title":"Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide","volume":"134","author":"Bisogno","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1056\/NEJMra1801490","article-title":"Psychotic Disorders","volume":"379","author":"Lieberman","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1177\/0269881114565142","article-title":"The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects","volume":"29","author":"Brunt","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/15504263.2019.1674991","article-title":"Cannabis Use and the Risk for Psychosis and Affective Disorders","volume":"16","author":"Sideli","year":"2020","journal-title":"J. Dual Diagn."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Bl\u00e1zquez, P., Rodr\u00edguez-Mu\u00f1oz, M., and Garz\u00f3n, J. (2014). The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: Implications in psychosis and schizophrenia. Front. Pharmacol., 4.","DOI":"10.3389\/fphar.2013.00169"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0074-7742(06)78003-5","article-title":"Glutamate and Schizophrenia: Phencyclidine, N-Methyl-d-Aspartate Receptors, and Dopamine\u2013Glutamate Interactions","volume":"78","author":"Javitt","year":"2007","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2174\/1568026023393507","article-title":"Subunit Composition, Distribution and Function of GABA-A Receptor Subtypes","volume":"2","author":"Sieghart","year":"2002","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"40224","DOI":"10.1074\/jbc.R112.386664","article-title":"Structure, Function, and Modulation of GABAA Receptors","volume":"287","author":"Sigel","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.neuron.2011.12.012","article-title":"Extrasynaptic GABAA Receptors: Their Function in the CNS and Implications for Disease","volume":"73","author":"Brickley","year":"2012","journal-title":"Neuron"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/10799890600920035","article-title":"GABA A Receptors in Central Nervous System Disease: Anxiety, Epilepsy, and Insomnia","volume":"26","year":"2006","journal-title":"J. Recept. Signal Transduct."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nrd3502","article-title":"Beyond classical benzodiazepines: Novel therapeutic potential of GABAA receptor subtypes","volume":"10","author":"Rudolph","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00424-011-0988-4","article-title":"GABAA receptors involved in sleep and anaesthesia: \u03b21- versus \u03b23-containing assemblies","volume":"463","author":"Yanovsky","year":"2012","journal-title":"Pfl\u00fcgers Arch. Eur. J. Physiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/bs.apha.2014.11.005","article-title":"Allosteric Ligands and Their Binding Sites Define \u03b3-Aminobutyric Acid (GABA) Type a Receptor Subtypes","volume":"73","author":"Olsen","year":"2015","journal-title":"Adv. Pharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41586-020-2654-5","article-title":"Shared structural mechanisms of general anaesthetics and benzodiazepines","volume":"585","author":"Kim","year":"2020","journal-title":"Nature"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41586-018-0255-3","article-title":"Structure of a human synaptic GABAA receptor","volume":"559","author":"Zhu","year":"2018","journal-title":"Nature"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41586-018-0832-5","article-title":"GABAA receptor signalling mechanisms revealed by structural pharmacology","volume":"565","author":"Masiulis","year":"2019","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"18150","DOI":"10.1073\/pnas.1113444108","article-title":"The major central endocannabinoid directly acts at GABAA receptors","volume":"108","author":"Sigel","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.phrs.2017.02.022","article-title":"The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABA A receptors","volume":"119","author":"Bakas","year":"2017","journal-title":"Pharmacol. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.neuron.2005.01.028","article-title":"The \u03b2 Subunit Determines the Ligand Binding Properties of Synaptic Glycine Receptors","volume":"45","author":"Grudzinska","year":"2005","journal-title":"Neuron"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/0896-6273(95)90145-0","article-title":"Identification of a gephyrin binding motif on the glycine receptor \u03b2 subunit","volume":"15","author":"Meyer","year":"1995","journal-title":"Neuron"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1002\/j.1460-2075.1991.tb07779.x","article-title":"Widespread expression of glycine receptor subunit mRNAs in the adult and developing rat brain","volume":"10","author":"Malosio","year":"1991","journal-title":"EMBO J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/mp.2015.139","article-title":"Genetic and functional analyses demonstrate a role for abnormal glycinergic signaling in autism","volume":"21","author":"Pilorge","year":"2016","journal-title":"Mol. Psychiatry"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1172\/JCI71472","article-title":"Changes in neural network homeostasis trigger neuropsychiatric symptoms","volume":"124","author":"Winkelmann","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000201556","article-title":"The Nonpsychotropic Cannabinoid Cannabidiol Modulates and Directly Activates Alpha-1 and Alpha-1-Beta Glycine Receptor Function","volume":"83","author":"Ahrens","year":"2009","journal-title":"Pharmacology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1084\/jem.20120242","article-title":"Cannabinoids suppress inflammatory and neuropathic pain by targeting \u03b13 glycine receptors","volume":"209","author":"Xiong","year":"2012","journal-title":"J. Exp. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00210-010-0506-9","article-title":"Lack of positive allosteric modulation of mutated \u03b11S267I glycine receptors by cannabinoids","volume":"381","author":"Foadi","year":"2010","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1124\/pr.118.015487","article-title":"5-HT 3 Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: The Iceberg Still Lies beneath the Surface","volume":"71","author":"Fakhfouri","year":"2019","journal-title":"Pharmacol. Rev."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1038\/tp.2012.30","article-title":"Replication of functional serotonin receptor type 3A and B variants in bipolar affective disorder: A European multicenter study","volume":"2","author":"Hammer","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/med.21666","article-title":"Recent advances with 5-HT 3 modulators for neuropsychiatric and gastrointestinal disorders","volume":"40","author":"Juza","year":"2020","journal-title":"Med. Res. Rev."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/jpet.109.162594","article-title":"The Nonpsychoactive Cannabinoid Cannabidiol Inhibits 5-Hydroxytryptamine 3A Receptor-Mediated Currents in Xenopus laevis Oocytes","volume":"333","author":"Yang","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/39807","article-title":"The capsaicin receptor: A heat-activated ion channel in the pain pathway","volume":"389","author":"Caterina","year":"1997","journal-title":"Nature"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature12823","article-title":"TRPV1 structures in distinct conformations reveal activation mechanisms","volume":"504","author":"Cao","year":"2013","journal-title":"Nature"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nature12822","article-title":"Structure of the TRPV1 ion channel determined by electron cryo-microscopy","volume":"504","author":"Liao","year":"2013","journal-title":"Nature"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nature17964","article-title":"TRPV1 structures in nanodiscs reveal mechanisms of ligand and lipid action","volume":"534","author":"Gao","year":"2016","journal-title":"Nature"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Vitale, R.M., Moriello, A.S., and De Petrocellis, L. (2020). Chapter 6. Natural Compounds and Synthetic Drugs Targeting the Ionotropic Cannabinoid Members of Transient Receptor Potential (TRP) Channels. New Tools to Interrogate Endocannabinoid Signalling: From Natural Compounds to Synthetic Drugs, The Royal Society of Chemistry.","DOI":"10.1039\/9781839160752-00201"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.neuron.2007.12.027","article-title":"TRPV1 Channels Mediate Long-Term Depression at Synapses on Hippocampal Interneurons","volume":"57","author":"Gibson","year":"2008","journal-title":"Neuron"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.neuron.2008.02.023","article-title":"Hotheaded: TRPV1 as Mediator of Hippocampal Synaptic Plasticity","volume":"57","author":"Alter","year":"2008","journal-title":"Neuron"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11010-018-3439-0","article-title":"Inhibitions of anandamide transport and FAAH synthesis decrease apoptosis and oxidative stress through inhibition of TRPV1 channel in an in vitro seizure model","volume":"453","author":"Taner","year":"2019","journal-title":"Mol. Cell. Biochem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.bbrc.2008.10.152","article-title":"TRPV1 stimulation triggers apoptotic cell death of rat cortical neurons","volume":"377","author":"Shirakawa","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.expneurol.2010.01.021","article-title":"Effects of TRPV1 activation on synaptic excitation in the dentate gyrus of a mouse model of temporal lobe epilepsy","volume":"223","author":"Bhaskaran","year":"2010","journal-title":"Exp. Neurol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.yebeh.2013.10.022","article-title":"Role of TRPV1 in susceptibility to PTZ-induced seizure following repeated hyperthermia challenges in neonatal mice","volume":"31","author":"Kong","year":"2014","journal-title":"Epilepsy Behav."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bbi.2015.01.017","article-title":"TRPV1 promotes repetitive febrile seizures by pro-inflammatory cytokines in immature brain","volume":"48","author":"Huang","year":"2015","journal-title":"Brain. Behav. Immun."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/1570159X13666150216222543","article-title":"TRPV1 Channel: A Potential Drug Target for Treating Epilepsy","volume":"13","year":"2015","journal-title":"Curr. Neuropharmacol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s12031-012-9878-2","article-title":"Increased Expression of TRPV1 in the Cortex and Hippocampus from Patients with Mesial Temporal Lobe Epilepsy","volume":"49","author":"Sun","year":"2013","journal-title":"J. Mol. Neurosci."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1111\/j.1432-1033.2004.04082.x","article-title":"Biochemical pharmacology of the vanilloid receptor TRPV1","volume":"271","author":"Cortright","year":"2004","journal-title":"An update. Eur. J. Biochem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1021\/cn5000524","article-title":"Nonpsychotropic Plant Cannabinoids, Cannabidivarin (CBDV) and Cannabidiol (CBD), Activate and Desensitize Transient Receptor Potential Vanilloid 1 (TRPV1) Channels in Vitro: Potential for the Treatment of Neuronal Hyperexcitability","volume":"5","author":"Iannotti","year":"2014","journal-title":"ACS Chem. Neurosci."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"134823","DOI":"10.1016\/j.neulet.2020.134823","article-title":"Proconvulsant effect of trans-cinnamaldehyde in pentylenetetrazole-induced kindling model of epilepsy: The role of TRPA1 channels","volume":"721","author":"Arslan","year":"2020","journal-title":"Neurosci. Lett."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1089\/can.2016.0034","article-title":"An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies","volume":"2","author":"Iffland","year":"2017","journal-title":"Cannabis Cannabinoid Res."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Ramsay, R.R., Popovic-Nikolic, M.R., Nikolic, K., Uliassi, E., and Bolognesi, M.L. (2018). A perspective on multi-target drug discovery and design for complex diseases. Clin. Transl. Med., 7.","DOI":"10.1186\/s40169-017-0181-2"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.lfs.2005.05.055","article-title":"Cannabinoid signalling","volume":"78","author":"Demuth","year":"2006","journal-title":"Life Sci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"7958","DOI":"10.1523\/JNEUROSCI.0247-14.2014","article-title":"Presynaptic Calcium Channel Inhibition Underlies CB1 Cannabinoid Receptor-Mediated Suppression of GABA Release","volume":"34","author":"Szabo","year":"2014","journal-title":"J. Neurosci."},{"key":"ref_98","unstructured":"(2018). Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. Int. J. Mol. Sci., 19."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1152\/jn.2001.85.1.468","article-title":"CB1 Cannabinoid Receptor Inhibits Synaptic Release of Glutamate in Rat Dorsolateral Striatum","volume":"85","author":"Gerdeman","year":"2001","journal-title":"J. Neurophysiol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1756-6606-6-42","article-title":"HINT1 protein cooperates with cannabinoid 1 receptor to negatively regulate glutamate NMDA receptor activity","volume":"6","year":"2013","journal-title":"Mol. Brain"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.neuropharm.2017.05.018","article-title":"Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities","volume":"124","author":"Khurana","year":"2017","journal-title":"Neuropharmacology"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/nature23272","article-title":"Crystal structures of agonist-bound human cannabinoid receptor CB1","volume":"547","author":"Hua","year":"2017","journal-title":"Nature"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.cell.2016.10.004","article-title":"Crystal Structure of the Human Cannabinoid Receptor CB1","volume":"167","author":"Hua","year":"2016","journal-title":"Cell"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/s41589-019-0387-2","article-title":"Structure of an allosteric modulator bound to the CB1 cannabinoid receptor","volume":"15","author":"Shao","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.biochi.2018.10.015","article-title":"The 5-HT1A receptor: Signaling to behavior","volume":"161","author":"Albert","year":"2019","journal-title":"Biochimie"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1098\/rstb.2011.0376","article-title":"Transcriptional regulation of the 5-HT 1A receptor: Implications for mental illness","volume":"367","author":"Albert","year":"2012","journal-title":"Philos. Trans. R. Soc. B Biol. Sci."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00213-013-3389-x","article-title":"5-HT1A receptors in mood and anxiety: Recent insights into autoreceptor versus heteroreceptor function","volume":"231","author":"Leonardo","year":"2014","journal-title":"Psychopharmacology"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","article-title":"Agonistic Properties of Cannabidiol at 5-HT1a Receptors","volume":"30","author":"Russo","year":"2005","journal-title":"Neurochem. Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1111\/j.1476-5381.2011.01621.x","article-title":"Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT1A somatodendritic autoreceptors in the dorsal raphe nucleus","volume":"165","author":"Rock","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1476-5381.2009.00521.x","article-title":"Antidepressant-like effects of cannabidiol in mice: Possible involvement of 5-HT1A receptors","volume":"159","author":"Zanelati","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00213-008-1168-x","article-title":"Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats","volume":"199","author":"Campos","year":"2008","journal-title":"Psychopharmacology"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.bbr.2016.01.033","article-title":"Antidepressant-like effect of cannabidiol injection into the ventral medial prefrontal cortex\u2014Possible involvement of 5-HT1A and CB1 receptors","volume":"303","author":"Sartim","year":"2016","journal-title":"Behav. Brain Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.pnpbp.2018.06.002","article-title":"Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels","volume":"86","author":"Sales","year":"2018","journal-title":"Prog. Neuro Psychopharmacol. Biol. Psychiatry"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1038\/npp.2016.93","article-title":"Cannabidiol Modulates Fear Memory Formation Through Interactions with Serotonergic Transmission in the Mesolimbic System","volume":"41","author":"Norris","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.bbrc.2017.05.165","article-title":"GPR3 and GPR6, novel molecular targets for cannabidiol","volume":"490","author":"Laun","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Valverde, O., C\u00e9l\u00e9rier, E., Baranyi, M., Vanderhaeghen, P., Maldonado, R., Sperlagh, B., Vassart, G., and Ledent, C. (2009). GPR3 Receptor, a Novel Actor in the Emotional-Like Responses. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0004704"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.expneurol.2014.04.010","article-title":"G-protein coupled receptor 6 deficiency alters striatal dopamine and cAMP concentrations and reduces dyskinesia in a mouse model of Parkinson\u2019s disease","volume":"257","author":"Oeckl","year":"2014","journal-title":"Exp. Neurol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"14109","DOI":"10.3390\/ijms160614109","article-title":"Novel Therapeutic GPCRs for Psychiatric Disorders","volume":"16","author":"Komatsu","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e00933","DOI":"10.1016\/j.heliyon.2018.e00933","article-title":"Novel inverse agonists for the orphan G protein-coupled receptor 6","volume":"4","author":"Laun","year":"2018","journal-title":"Heliyon"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/sj.bjp.0707460","article-title":"The orphan receptor GPR55 is a novel cannabinoid receptor","volume":"152","author":"Ryberg","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0169-328X(98)00277-0","article-title":"Identification and cloning of three novel human G protein-coupled receptor genes GPR52, \u03a8GPR53 and GPR55: GPR55 is extensively expressed in human brain","volume":"64","author":"Sawzdargo","year":"1999","journal-title":"Mol. Brain Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13041-017-0318-7","article-title":"The novel cannabinoid receptor GPR55 mediates anxiolytic-like effects in the medial orbital cortex of mice with acute stress","volume":"10","author":"Shi","year":"2017","journal-title":"Mol. Brain"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"11229","DOI":"10.1073\/pnas.1711351114","article-title":"Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome","volume":"114","author":"Kaplan","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.neuron.2014.01.016","article-title":"Enhancement of Inhibitory Neurotransmission by GABA A Receptors Having \u03b1 2,3 -Subunits Ameliorates Behavioral Deficits in a Mouse Model of Autism","volume":"81","author":"Han","year":"2014","journal-title":"Neuron"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/nature17391","article-title":"Crystal structure of the human \u03c31 receptor","volume":"532","author":"Schmidt","year":"2016","journal-title":"Nature"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Smith, S., and Su, T.P. (2017). A Review of the Human Sigma-1 Receptor Structure. Sigma Receptors: Their Role in Disease and as Therapeutic Targets. Advances in Experimental Medicine and Biology, vol 964, Springer International Publishing.","DOI":"10.1007\/978-3-319-50174-1_1"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"35458","DOI":"10.18632\/oncotarget.6064","article-title":"The ON:OFF switch, \u03c31R-HINT1 protein, controls GPCR-NMDA receptor cross-regulation: Implications in neurological disorders","volume":"6","year":"2015","journal-title":"Oncotarget"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13041-018-0395-2","article-title":"Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures and reduces stroke damage via the sigma 1 receptor","volume":"11","author":"Onetti","year":"2018","journal-title":"Mol. Brain"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1111\/bph.13497","article-title":"An update on PPAR activation by cannabinoids","volume":"173","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Iannotti, F.A., and Vitale, R.M. (2021). The Endocannabinoid System and PPARs: Focus on Their Signalling Crosstalk, Action and Transcriptional Regulation. Cells, 10.","DOI":"10.3390\/cells10030586"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"12611","DOI":"10.1523\/JNEUROSCI.4127-15.2016","article-title":"Genetic Deletion of Neuronal PPAR\u03b3 Enhances the Emotional Response to Acute Stress and Exacerbates Anxiety: An Effect Reversed by Rescue of Amygdala PPAR\u03b3 Function","volume":"36","author":"Domi","year":"2016","journal-title":"J. Neurosci."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/npp.2014.268","article-title":"PPAR\u03b3 Activation Attenuates Opioid Consumption and Modulates Mesolimbic Dopamine Transmission","volume":"40","author":"Melis","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.biopsych.2010.12.010","article-title":"Activation of Nuclear PPAR\u03b3 Receptors by the Antidiabetic Agent Pioglitazone Suppresses Alcohol Drinking and Relapse to Alcohol Seeking","volume":"69","author":"Stopponi","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"768","DOI":"10.2174\/1389450111314070006","article-title":"Peroxisome Proliferator-Activated Receptor (PPAR) Agonists as Promising New Medications for Drug Addiction: Preclinical Evidence","volume":"14","author":"Panlilio","year":"2013","journal-title":"Curr. Drug Targets"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"9864","DOI":"10.1523\/JNEUROSCI.1922-19.2019","article-title":"Activation of PPAR\u03b3 Attenuates the Expression of Physical and Affective Nicotine Withdrawal Symptoms through Mechanisms Involving Amygdala and Hippocampus Neurotransmission","volume":"39","author":"Domi","year":"2019","journal-title":"J. Neurosci."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1111\/add.13868","article-title":"PPAR-gamma agonist pioglitazone modifies craving intensity and brain white matter integrity in patients with primary cocaine use disorder: A double-blind randomized controlled pilot trial","volume":"112","author":"Schmitz","year":"2017","journal-title":"Addiction"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.pbb.2017.10.002","article-title":"Pioglitazone, a PPAR\u03b3 agonist, reduces nicotine craving in humans, with marginal effects on abuse potential","volume":"163","author":"Jones","year":"2017","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_138","first-page":"576","article-title":"Cannabinoids go nuclear: Evidence for activation of peroxisome proliferator-activated receptors","volume":"152","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Jung, T., Hudson, R., Rushlow, W., and Laviolette, S.R. (2020). Functional interactions between cannabinoids, omega-3 fatty acids, and peroxisome proliferator-activated receptors: Implications for mental health pharmacotherapies. Eur. J. Neurosci., ejn.15023.","DOI":"10.1111\/ejn.15023"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.neubiorev.2017.02.006","article-title":"Neuronal and molecular effects of cannabidiol on the mesolimbic dopamine system: Implications for novel schizophrenia treatments","volume":"75","author":"Renard","year":"2017","journal-title":"Neurosci. Biobehav. Rev."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/9\/4876\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:57:14Z","timestamp":1760162234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/9\/4876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,5]]},"references-count":140,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["ijms22094876"],"URL":"https:\/\/doi.org\/10.3390\/ijms22094876","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,5]]}}}